Avacta GroupAVCTF 13 Receivables Turnover is 0.02 as of Dec. 2025. GuruFocus rates AVCTF with a GF Score™ of 13/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 843 Biotechnology companies, Avacta Group ranks worse than 99.05% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Avacta Group's Revenue for the
six
months ended in Dec. 2025 was $0.08 Mil. Avacta Group's average Accounts Receivable for the
six
months ended in Dec. 2025 was $4.03 Mil.
Hence, Avacta Group's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.02.
Avacta Group (OTCPK:AVCTF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Avacta Group Receivables Turnover Related Terms
Avacta Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Avacta Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVCTF vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Avacta Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Avacta Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a Receivables Turnover of 0.02 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Avacta Group and its competitors. According to the industry distribution chart, Avacta Group ranks #835 out of 843 companies in the Biotechnology industry, placing it in the top 99.1%.
Is Avacta Group's Receivables Turnover too high?
Avacta Group's current Receivables Turnover is 0.02. The Biotechnology industry median Receivables Turnover is 5.28. Avacta Group's value of 0.02 is 99.6% below this industry median. Based on the distribution chart, Avacta Group ranks #835 out of 843 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #835 out of 843 companies for Receivables Turnover. This places Avacta Group in the lower half of its industry. The industry median Receivables Turnover is 5.28. Avacta Group's value of 0.02 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Receivables Turnover of 0.02 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Receivables Turnover is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $1.00 — trading 49.3% above its estimated fair value. The current Receivables Turnover is 0.02 and 99.6% below the Biotechnology industry median of 5.28. Avacta Group's overall GF Score™ is 13/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Receivables Turnover is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $1.00 is trading 49.3% above its estimated GF Value™ of $0.67.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
Receivables Turnover: 0.02
GF Value™: $0.67 vs. price of $1.00 (49.3% above fair value)
Industry Position: 99.6% below the Biotechnology median (#835 of 843)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score
Get the complete analysis for AVCTF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
